|
|
|
|
|
|
Sponsors and Collaborators: |
University of Wisconsin, Madison Immunex Corporation |
Information provided by: | University of Wisconsin, Madison |
ClinicalTrials.gov Identifier: | NCT00205231 |
This pilot study will investigate the safety and effect of etanercept in HIV infection by studying HIV replication and immune function (as measured by CD4 counts) in individuals with HIV infection.
Condition | Intervention |
HIV Infections |
Drug: etanercept |
MedlinePlus related topics: | AIDS Cancer |
ChemIDplus related topics: | Etanercept Tumor Necrosis Factors |
Study Type: | Interventional |
Study Design: | Non-Randomized, Open Label, Dose Comparison, Parallel Assignment |
Official Title: | A Pilot Study to Examine the Feasibility and Effect on Tumor Necrosis Factor (TNF) Inhibition on HIV Disease |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Subject has any of the following laboratory values within 30 days of baseline:
Contact: Andrew Urban, MD | 608-256-1901 ext 17472 | Andrew.Urban@med.va.gov |
Contact: Frank Graziano, MD, PhD | 608-263-6186 | fmg@medicine.wisc.edu |
United States, Wisconsin | |||||
University of Wisconsin Hospital and Clinics | Recruiting | ||||
Madison, Wisconsin, United States, 53792 | |||||
Contact: Andrew Urban, MD 608-256-1901 ext 17472 andrew.urban@med.va.gov | |||||
Principal Investigator: Andrew Urban, MD |
University of Wisconsin, Madison |
Immunex Corporation |
Principal Investigator: | Andrew Urban, MD | University of Wisconsin Hospital and Clinics |
Study ID Numbers: | 2001-557 |
First Received: | September 13, 2005 |
Last Updated: | October 24, 2007 |
ClinicalTrials.gov Identifier: | NCT00205231 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|